BRD9 and myelodysplastic syndrome: Although ncBAF-specific components (BRD9, GLTSCR1, and GLTSCR1L) are rarely mutated in cancer, we recently identified that BRD9 is substantially downregulated due to mRNA degradation from mis-splicing by mutations in the spliceosomal protein, SF3B116, which occur in ~30% of myelodysplastic syndrome (MDS) patients17,18.